These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36867396)

  • 1. Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective.
    Li X; Warren S; Rozenbaum MH; Perdrizet J
    Infect Dis Ther; 2023 Mar; 12(3):997-1006. PubMed ID: 36867396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
    Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
    Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
    Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
    BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India.
    Ghia CJ; Horn EK; Rambhad G; Perdrizet J; Chitale R; Wasserman MD
    Infect Dis Ther; 2021 Dec; 10(4):2271-2288. PubMed ID: 34313958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
    Wilson M; Wasserman M; Jadavi T; Postma M; Breton MC; Peloquin F; Earnshaw S; McDade C; Sings H; Farkouh R
    Infect Dis Ther; 2018 Sep; 7(3):353-371. PubMed ID: 29934878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States.
    Perdrizet J; Horn EK; Hayford K; Grant L; Barry R; Huang L; McDade C; Wilson M
    Infect Dis Ther; 2023 May; 12(5):1351-1364. PubMed ID: 37079175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
    Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
    Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Clin Infect Dis; 2023 Feb; 76(3):e1062-e1070. PubMed ID: 35789262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.
    Ansaldi F; Pugh S; Amicizia D; Di Virgilio R; Trucchi C; Orsi A; Zollo A; Icardi G
    Pathogens; 2020 Jan; 9(2):. PubMed ID: 31979079
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
    Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
    J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.
    Perdrizet J; Horn EK; Nua W; Perez-Peralta J; Nailes J; Santos J; Ong-Lim A
    Infect Dis Ther; 2021 Dec; 10(4):2625-2642. PubMed ID: 34591259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.
    Mohanty S; Hu T; Yang G; Khan TK; Owusu-Edusei K; Sukarom I
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046433. PubMed ID: 35420975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.
    Kim HY; Park SB; Kang ES; Lee SM; Kim HJ; Wasserman M
    Hum Vaccin Immunother; 2021 Mar; 17(3):909-918. PubMed ID: 32783576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA.
    Owusu-Edusei K; Deb A; Johnson KD
    Infect Dis Ther; 2022 Jun; 11(3):987-999. PubMed ID: 35084647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.